Recursion Pharmaceuticals Inc (RXRX)
6.40
+0.08
(+1.27%)
USD |
NASDAQ |
Nov 01, 16:00
6.405
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Enterprise Value: 1.363B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 1.363B |
| October 31, 2024 | 1.340B |
| October 30, 2024 | 1.442B |
| October 29, 2024 | 1.459B |
| October 28, 2024 | 1.496B |
| October 25, 2024 | 1.386B |
| October 24, 2024 | 1.352B |
| October 23, 2024 | 1.343B |
| October 22, 2024 | 1.422B |
| October 21, 2024 | 1.465B |
| October 18, 2024 | 1.515B |
| October 17, 2024 | 1.405B |
| October 16, 2024 | 1.535B |
| October 15, 2024 | 1.439B |
| October 14, 2024 | 1.453B |
| October 11, 2024 | 1.425B |
| October 10, 2024 | 1.301B |
| October 09, 2024 | 1.292B |
| October 08, 2024 | 1.374B |
| October 07, 2024 | 1.301B |
| October 04, 2024 | 1.281B |
| October 03, 2024 | 1.267B |
| October 02, 2024 | 1.281B |
| October 01, 2024 | 1.298B |
| September 30, 2024 | 1.417B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.527B |
| September 26, 2024 | 1.580B |
| September 25, 2024 | 1.501B |
| September 24, 2024 | 1.487B |
| September 23, 2024 | 1.439B |
| September 20, 2024 | 1.476B |
| September 19, 2024 | 1.515B |
| September 18, 2024 | 1.507B |
| September 17, 2024 | 1.465B |
| September 16, 2024 | 1.434B |
| September 13, 2024 | 1.411B |
| September 12, 2024 | 1.391B |
| September 11, 2024 | 1.377B |
| September 10, 2024 | 1.340B |
| September 09, 2024 | 1.284B |
| September 06, 2024 | 1.228B |
| September 05, 2024 | 1.298B |
| September 04, 2024 | 1.278B |
| September 03, 2024 | 1.270B |
| August 30, 2024 | 1.611B |
| August 29, 2024 | 1.648B |
| August 28, 2024 | 1.637B |
| August 27, 2024 | 1.705B |
| August 26, 2024 | 1.784B |
| August 23, 2024 | 1.761B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
276.51M
Minimum
May 11 2022
6.341B
Maximum
Jul 13 2021
1.831B
Average
1.459B
Median
Aug 16 2024
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Pfizer Inc | 221.03B |
| Revance Therapeutics Inc | 802.59M |
| Twist Bioscience Corp | 2.146B |
| NovaBay Pharmaceuticals Inc | 3.615M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -97.54M |
| Revenue (Quarterly) | 14.40M |
| Total Expenses (Quarterly) | 114.95M |
| EPS Diluted (Quarterly) | -0.40 |
| Gross Profit Margin (Quarterly) | 36.14% |
| Profit Margin (Quarterly) | -677.2% |
| Earnings Yield | -25.62% |
| Normalized Earnings Yield | -25.62 |